Abstract

Doxorubicin is one of the most important anticancer agents, but its clinical uses are limited due to cardiotoxicity, the present study evaluated the effects of new derivatives of doxorubicin on cardiac tissue by the measurement of serum cardiac troponin I (cTnI) and CK-BM assays as biomarkers as well as heart tissue after 3 weeks of treatment in albino mice. The results indicated that TnI was significantly elevated (P≤ 0.05) in all studied groups when compared with the control, also serum CK-MB was significantly elevated (P≤ 0.05) in all studied groups except that treated with a new compound when compared with the control group. The histopathological study of heart tissue revealed that the treatment with this compound showed less changes in heart tissue.